Therapy for Apnoea of Prematurity: A Retrospective Study on Effects of Standard Dose and Genetic Variability on Clinical Response to Caffeine Citrate in Chinese Preterm Infants
- 12 November 2020
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 38 (1) , 607-626
Abstract
Introduction Apnoea of prematurity (AOP) is among the most common diagnoses in the neonatal intensive care unit. Caffeine treatment is a preferred treatment choice. However, neonatal caffeine therapy results in significant intersubject variability. This study aimed to determine the effects of plasma caffeine levels based on standard dose and genetic variability on clinical response to caffeine citrate in Chinese preterm infants. Methods This single-center and retrospective study examined data from 112 preterm infants (< 35 weeks gestational age) between July 2017 and July 2018. Subjects were divided into apnoea-free (n = 48) and apnoeic (n = 64) groups, and their clinical outcomes were summarized. Liquid chromatography-tandem mass spectrometry was used to measure levels of caffeine and its primary metabolites. Eighty-eight single-nucleotide polymorphisms were chosen for genotyping by a MassARRAY system. Results Preterm infants in the apnoea-free group were associated with a reduction in the incidence of bronchopulmonary dysplasia and a reduced requirement for patent ductus arteriosus ligation. No significant association was observed between plasma-trough-concentration-to-dose (C0/D) ratio and birth weight, gestational age, or postnatal age in either group. Polymorphisms in CYP1A2 and aryl hydrocarbon receptor (AHR) genes did not affect plasma caffeine levels. Polymorphisms in adenosine receptor genes ADORA1 (rs10920568 and rs12744240), ADORA2A (rs34923252 and rs5996696), and ADORA3 (rs10776727 and rs2298191), especially in AHR (rs4410790) and adenosine deaminase (rs521704), play critical roles in the interindividual response to caffeine therapy. Conclusions Genetic polymorphisms in caffeine’s target receptors, but not the exposure levels based on the standard dosing, were associated with variable responses to caffeine therapy in preterm neonates. Future studies are needed to uncover how these genetic variants affect responses to caffeine therapy in this patient population.Keywords
Funding Information
- the Specially Appointed Medical Expert Project of Jiangsu Commission of Health (2019)
- Special Fund for Clinical Research of Wu Jieping Medical Foundation (320.6750.2020-04-07)
- Children’s Hospital of Nanjing Medical University (ETYYQM2014024)
- Nanjing Medical University Science and Technology Development Foundation (NMUB2019195)
This publication has 37 references indexed in Scilit:
- Adenosine receptors as drug targets — what are the challenges?Nature Reviews Drug Discovery, 2013
- PharmGKB summaryPharmacogenetics and Genomics, 2012
- Genetic basis of apnoea of prematurity and caffeine treatment response: role of adenosine receptor polymorphismsActa Paediatrica, 2012
- Neonatal outcomes of preterm infants in breech presentation according to mode of birth in Canadian NICUsPostgraduate Medical Journal, 2011
- Transcriptional Factor Aryl Hydrocarbon Receptor (Ahr) Controls Cardiovascular and Respiratory Functions by Regulating the Expression of the Vav3 Proto-oncogeneJournal of Biological Chemistry, 2011
- Heritability of Apnea of Prematurity: A Retrospective Twin StudyPediatrics, 2010
- Long-Term Effects of Caffeine Therapy for Apnea of PrematurityNew England Journal of Medicine, 2007
- Caffeine Therapy for Apnea of PrematurityNew England Journal of Medicine, 2006
- Apnea, Sudden Infant Death Syndrome, and Home MonitoringPediatrics, 2003
- Incidence and evolution of subependymal and intraventricular hemorrhage: A study of infants with birth weights less than 1,500 gmThe Journal of Pediatrics, 1978